Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to evaluate the use of Rituximab in combination with Revlimid
in the treatment of refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia
(CLL). Revlimid® is a drug that changes the immune system and it may also get in the way with
the growth of tiny blood vessels that help support tumor growth. Therefore, in theory, it may
reduce or prevent the growth of cancer cells. Revlimid® is approved by the Food and Drug
Administration (FDA) for the treatment of specific types of Myelodysplasia syndrome (MDS) and
Multiple Myeloma, two different types of blood cancer. It is currently being tested in a
variety of cancer conditions. In this case it is considered experimental.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute